Search | IOVS | ARVO Journals

View

Showing 1 – 20 of 26

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2020

In Vitro Antibiotic Resistance of Ocular Bacterial Pathogens – An Update from the 2019 ARMOR Study

Christine M Sanfilippo; Heleen DeCory; Penny A Asbell

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2978. doi:

ARVO Annual Meeting Abstract June 2020

Trends in Antibiotic Resistance Over Time Among Staphylococci Collected 2009-2019 in the ARMOR Study

Penny A Asbell; Christine M Sanfilippo; Heleen DeCory

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4885. doi:

ARVO Annual Meeting Abstract July 2019

Incidence of Polybacterial Infections in Three Bacterial Conjunctivitis Studies and Outcomes with Besifloxacin Ophthalmic Suspension 0.6%

Joseph M Blondeau; Christine M Sanfilippo; Heleen H DeCory

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):245. doi:

ARVO Annual Meeting Abstract July 2019

Antibiotic Resistance Among Ocular Pathogens – An Update from the 2018 ARMOR Study

Christine M Sanfilippo; Heleen H DeCory; Penny A Asbell

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):246. doi:

ARVO Annual Meeting Abstract July 2019

Longitudinal Trends in Antibiotic Resistance Among Staphylococci Collected in the ARMOR Study

Penny A Asbell; Christine M Sanfilippo; Heleen H DeCory

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):853. doi:

ARVO Annual Meeting Abstract July 2018

Antibiotic Resistance in Ocular Pathogens – Preliminary Results from the 2017 ARMOR Surveillance Program

Christine M Sanfilippo; Megan E Cavet; Heleen DeCory; Penny A Asbell

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2659. doi:

ARVO Annual Meeting Abstract July 2018

Antibiotic Resistance Trends Among Staphylococci in the ARMOR Study: 2009-2017

Penny A Asbell; Christine M Sanfilippo; Megan E Cavet; Heleen DeCory

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3676. doi:

ARVO Annual Meeting Abstract June 2017

Eight-Year Longitudinal Trends in Methicillin Resistance and Resistance to Other Antibiotics Among Staphylococci From the ARMOR Surveillance Study

Heleen H DeCory; Christine M Sanfilippo; Penny A Asbell

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):3874. doi:

ARVO Annual Meeting Abstract June 2017

Assessment of ophthalmic steroid class adverse event reports for loteprednol etabonate

Megan E Cavet; Christine M Sanfilippo; Heleen H DeCory

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1082. doi:

ARVO Annual Meeting Abstract June 2017

Antibiotic Resistance in Ocular Pathogens – An Update from the 2016 ARMOR Surveillance Program

Christine M Sanfilippo; Heleen H DeCory; Daniel F Sahm; Penny A Asbell

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1083. doi:

ARVO Annual Meeting Abstract September 2016

Antibiotic Resistance Profiles of Ocular Pathogens – An Update from the 2015 ARMOR Surveillance Study

Christine M Sanfilippo; Heleen H DeCory; Daniel F Sahm; Penny A Asbell

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5404. doi:

ARVO Annual Meeting Abstract September 2016

In Vitro Antibiotic Susceptibility of Ocular Pathogens Collected from the Aqueous and Vitreous Humor during the ARMOR Surveillance Study

Penny A Asbell; Heleen H DeCory; Daniel F Sahm; Christine M Sanfilippo

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2348. doi:

ARVO Annual Meeting Abstract June 2015

Antibiotic Resistance Among Ocular Pathogens - Results from the ARMOR Surveillance Study 2013-Present

Penny A Asbell; Christine M Sanfilippo; Daniel F Sahm; Heleen H DeCory

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):284. doi:

ARVO Annual Meeting Abstract April 2014

Antibacterial Susceptibility of Coagulase Negative Staph Before and After Prophylactic Use of Besifloxacin and Moxifloxacin

Frank A Bucci; Christine M Sanfilippo; Heleen H DeCory; Loretta Amico; Ruth E Evans; Timothy L Comstock

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1489. doi:

ARVO Annual Meeting Abstract April 2014

In vitro Antibiotic Susceptibility Profile of Ocular Pathogens - Results from the First ARMOR Canada Surveillance Study

Joseph M Blondeau; Christine M Sanfilippo; Timothy W Morris; Jennifer Deane; Daniel F Sahm

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):2840. doi:

ARVO Annual Meeting Abstract April 2014

Antibiotic Resistance Profile of Ocular Pathogens - An Update from the 2013 US ARMOR Surveillance Study

Christine M Sanfilippo; Timothy W Morris; Jennifer Deane; Deborah C Draghi; Daniel F Sahm

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):6281. doi:

ARVO Annual Meeting Abstract March 2012

Strain ST448 Causes the Majority of Pneumococcal Conjunctivitis Cases

Christine M. Sanfilippo; Wolfgang Haas; Christine K. Hesje; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):83. doi:

ARVO Annual Meeting Abstract March 2012

Microbiological Eradication Rates with BID or TID Dosing of Besifloxacin Ophthalmic Suspension, 0.6% in Bacterial Conjunctivitis Clinical Trials from 2004 - 2010

Kirk Bateman; Timothy L. Comstock; Lynne S. Gearinger; Christine K. Hesje; Christine M. Sanfilippo; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6198. doi:

ARVO Annual Meeting Abstract April 2011

Comparative In Vitro Activity of Ophthalmic Antibacterials Against Ocular Pathogens From a 2009 - 2010 Bacterial Conjunctivitis Clinical Study

Lynne S. Gearinger; Kirk M. Bateman; Christine K. Hesje; Christine M. Sanfilippo; Timothy W. Morris

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):1462. doi:

ARVO Annual Meeting Abstract April 2011

Multi-drug Resistance Among 302 Streptococcus Pneumoniae Bacterial Conjunctivitis Isolates

Christine M. Sanfilippo; Christine K. Hesje; Timothy W. Morris; Wolfgang Haas

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):1489. doi:

1 2

Next 20 Results »

Advertisement